The FDA approved pembrolizumab (Keytruda, Merck) to be used with gemcitabine and cisplatin for locally advanced, unresectable or metastatic biliary tract cancer.
Efficacy was evaluated in KEYNOTE-966, a multicenter, randomized, double-blind, placebo-controlled trial that enrolled 1,069 patients with locally advanced, unresectable or metastatic biliary tract cancer who had not received prior systemic therapy for advanced disease. Patients were randomized in a 1:1 fashion to receive either
NOVEMBER 1, 2023